$ATEX

YAZDI MAHVASH sold $560K of ATEX

YAZDI MAHVASH sold 7,000 shares of Anterix Inc. (ATEX) at $80.00 ($0.56M total) on 2026-06-16.

Original reporting
SEC EDGAR · YAZDI MAHVASH
Published Jun 17, 2026, 11:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 11:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ATEX
Neutral
high confidence
Mentioned
$ATEX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATEXNeutralLow
01

Why it matters

The newest disclosed fact is the director’s open-market sale details (shares, price, total value, post-transaction holdings).

02

Market read

Traders may monitor ATEX for sentiment effects from insider selling, but the disclosure alone is unlikely to drive a durable repricing.

03

What to watch

The filing doesn’t state motives, and the remaining holdings (19,407 shares) suggest the director didn’t exit the position.

Relevance 5/10Novelty 6/10Timing: Filed 2026-06-17 (after 2026-06-16 sale)

Background

SEC Form 4 reports insider transactions for Anterix Inc. (ATEX).

Company-level read

Ticker impact

$ATEXNeutralHigh confidence
Context

Anterix (ATEX) disclosed via Form 4 that director Yazdi Mahvash sold 7,000 shares at $80/share for ~$560k on 2026-06-16.

Expected impact

Low likelihood of sustained price impact; any reaction is likely short-lived unless paired with other disclosures.

Evidence & confidence

The filing is a Form 4 insider sale with no 10b5-1 plan and no accompanying company-specific operational/regulatory catalyst in the text.

Market effects

Minimal; this is a single-company insider transaction with no sector-wide datapoint.

None indicated.

None indicated.

Counterpoint

Without a 10b5-1 plan, the sale could still be non-informational (tax/liquidity), so the market may overreact.

Key entities

  • Anterix Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Yazdi Mahvash

    Director who sold 7,000 shares at $80/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ATEXMed

Is Anterix (ATEX) Quietly Reframing Its Connectivity Moat With New 900 MHz FCC Flexibility?

Anterix (ATEX) gained attention after the FCC approved expanded 900 MHz broadband use and granted it a license for satellite testing. This could broaden its network applications and reinforce its investment narrative, though profitability currently relies heavily on noncash spectrum gains. Analysts project $6.9M revenue and $935K earnings by 2028, with a potential 36% downside from current prices.

$ATEXMed

Anterix (ATEX) Q1 2027 Earnings Call Transcript

Anterix (ATEX) reported Q1 2027 revenue of $2M, up from $1.4M YoY, with net income of $240K. Operating expenses decreased to $12.9M. The company has $116M in cash, no debt, and $226.7M left for share repurchases. Management highlighted 12 active deals, spectrum clearing progress, and support for SpaceX's FCC proposal. CFO warned of potential higher costs if spectrum clearing is accelerated.

$ATEXMed

Anterix Inc. (ATEX): Results of Operations and Financial Condition

Anterix Inc. (ATEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Anterix Inc. Reports First Quarter Fiscal Year 2027 Results Woodland Park, NJ – August 11, 2026 – Anterix (NASDAQ: ATEX) today announced its first quarter fiscal 2027 results and filed its Form 10-Q for the three months ended June 30, 2026. Financial and Operational Highlights –

$ATEXMed

Anterix Inc. (ATEX): Results of Operations and Financial Condition

Anterix Inc. (ATEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atex-20260331xpressrelease.htm EX-99.1 Document Anterix Inc. Reports Full Fiscal Year 2026 Results Woodland Park, NJ – June 10, 2026 – Anterix (NASDAQ: ATEX) today announced fiscal 2026 fourth quarter and full fiscal year financial results for the year ended March 31, 2